Wegovy is a new medication approved by the FDA in June 2021 for chronic weight management in adults who are overweight or have obesity. It is a subcutaneous injection that contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. According to the official Wegovy website [2], the most common side effects of Wegovy are gastrointestinal and include nausea, diarrhea, vomiting, constipation, and abdominal pain. These side effects usually occur during the first few weeks of treatment and may decrease over time. In rare cases, Wegovy may cause pancreatitis, which is a potentially life-threatening inflammation of the pancreas. Therefore, patients should seek medical attention immediately if they experience severe and persistent abdominal pain. Additionally, Wegovy may increase the risk of thyroid cancer, so patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not take this medication. It is important to note that Wegovy is a prescription medication and should only be used under the supervision of a healthcare provider. Patients should inform their healthcare provider of any pre-existing medical conditions, medications, or supplements they are taking before starting Wegovy [3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/WEGOVY
[2] https://www.wegovy.com/taking-wegovy/side-effects.html
[3] https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014